GWM
LLY icon

Geneos Wealth Management’s Eli Lilly LLY Stock Holding History

Geneos Wealth Management’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.06M Buy
7,676
+353
+5% +$358K 0.16% 150
2025
Q4 		$7.87M Sell
7,323
-171
-2% -$164K 0.19% 134
2025
Q3 		$5.72M Sell
7,494
-1,514
-17% -$1.13M 0.15% 178
2025
Q2 		$7.02M Sell
9,008
-11,813
-57% -$9.18M 0.17% 149
2025
Q1 		$17.2M Buy
20,821
+12,240
+143% +$10.2M 0.25% 99
2024
Q4 		$6.62M Sell
8,581
-458
-5% -$379K 0.23% 97
2024
Q3 		$8.01M Sell
9,039
-39
-0.4% -$35.1K 0.31% 74
2024
Q2 		$8.22M Sell
9,078
-716
-7% -$573K 0.36% 58
2024
Q1 		$7.62M Buy
9,794
+563
+6% +$401K 0.35% 65
2023
Q4 		$5.38M Sell
9,231
-648
-7% -$378K 0.27% 92
2023
Q3 		$5.31M Buy
9,879
+89
+0.9% +$45.9K 0.27% 93
2023
Q2 		$4.59M Buy
9,790
+1,642
+20% +$689K 0.24% 115
2023
Q1 		$2.8M Sell
8,148
-818
-9% -$276K 0.17% 153
2022
Q4 		$3.28M Sell
8,966
-427
-5% -$151K 0.2% 127
2022
Q3 		$3.04M Sell
9,393
-4,177
-31% -$1.32M 0.21% 119
2022
Q2 		$4.41M Sell
13,570
-312
-2% -$93.7K 0.22% 112
2022
Q1 		$3.98M Sell
13,882
-1,013
-7% -$261K 0.17% 140
2021
Q4 		$4.11M Sell
14,895
-1,282
-8% -$325K 0.16% 149
2021
Q3 		$3.71M Sell
16,177
-112
-0.7% -$27.6K 0.14% 162
2021
Q2 		$3.81M Buy
16,289
+2,764
+20% +$555K 0.15% 153
2021
Q1 		$2.47M Buy
13,525
+246
+2% +$48.1K 0.07% 266
2020
Q4 		$2.37M Sell
13,279
-249
-2% -$37.2K 0.1% 212
2020
Q3 		$2.03M Sell
13,528
-550
-4% -$85.1K 0.11% 195
2020
Q2 		$2.29M Sell
14,078
-106
-0.7% -$16.3K 0.13% 171
2020
Q1 		$1.9M Buy
14,184
+199
+1% +$27.3K 0.13% 170
2019
Q4 		$1.84M Buy
13,985
+180
+1% +$20.9K 0.1% 215
2019
Q3 		$1.55M Sell
13,805
-10
-0.1% -$1.11K 0.09% 212
2019
Q2 		$1.53M Buy
13,815
+429
+3% +$50.5K 0.09% 209
2019
Q1 		$1.74M Sell
13,386
-119
-0.9% -$14.5K 0.11% 190
2018
Q4 		$1.54M Sell
13,505
-419
-3% -$46.8K 0.11% 185
2018
Q3 		$1.49M Buy
13,924
+1,213
+10% +$121K 0.1% 212
2018
Q2 		$1.08M Sell
12,711
-420
-3% -$34.5K 0.08% 211
2018
Q1 		$1.01M Sell
13,131
-353
-3% -$28.4K 0.09% 207
2017
Q4 		$1.14M Sell
13,484
-1,264
-9% -$108K 0.1% 190
2017
Q3 		$1.26M Buy
14,748
+254
+2% +$20.8K 0.13% 169
2017
Q2 		$1.19M Buy
14,494
+40
+0.3% +$3.26K 0.12% 161
2017
Q1 		$1.22M Sell
14,454
-108
-0.7% -$8.65K 0.13% 153
2016
Q4 		$1.07M Buy
14,562
+650
+5% +$48.4K 0.14% 152
2016
Q3 		$1.12M Buy
13,912
+850
+7% +$68K 0.15% 148
2016
Q2 		$1.03M Buy
13,062
+214
+2% +$16.1K 0.15% 149
2016
Q1 		$943K Buy
+12,848
New +$972K 0.14% 156

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geneos Wealth Management's LLY Position: Q1 2026 in Review

Geneos Wealth Management increased its Eli Lilly (LLY) stake by 4.8% in Q1 2026, buying an estimated $358K and bringing the position to 7,676 shares worth $7.06M. The position accounts for 0.16% of the portfolio, ranked #150.

Geneos Wealth Management first reported a position in LLY in Q1 2016 and has held it in 41 quarters since. The position peaked at $17.2M in Q1 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Geneos Wealth Management held 7,676 shares of Eli Lilly worth $7.06M as of Q1 2026.
  • Geneos Wealth Management bought 353 Eli Lilly shares in Q1 2026, an estimated $358K.
  • Eli Lilly made up 0.16% of Geneos Wealth Management's portfolio in Q1 2026, its #150 holding.
  • Geneos Wealth Management first reported a position in Eli Lilly in Q1 2016 and has held it in 41 quarters since.
  • Geneos Wealth Management's Eli Lilly position peaked at $17.2M in Q1 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.